Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells

Breast Cancer

Volumn 21, Issue 3, 2014, Pages 358-369

  Kuo, Chin Ho ^a   Lu, Yin Che ^a   Tseng, Ya Shin ^b   Shi, Chung Sheng ^c   Chen, Shu Hsin ^a   Chen, Ping Tzu ^a   Wu, Feng Ling ^a   Chang, Yi Ping ^a   Lee, Ying Ray ^a,d  

^a CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d Min Hwei College of Health Care Management   (Taiwan)

Author keywords

Apoptosis; Breast cancer; Cell cycle; Polyploidy; Reversine

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REVERSINE; UNCLASSIFIED DRUG; 2-(4-MORPHOLINOANILINO)-6-CYCLOHEXYLAMINOPURINE; MORPHOLINE DERIVATIVE; PURINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MCF 7 CELL LINE; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; BREAST NEOPLASMS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MCF-7 CELLS; MITOCHONDRIA; MORPHOLINES; POLYPLOIDY; PURINES;

EID: 84901374490     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0400-z     Document Type: Article

References (40)

1. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist. 2004;9:617-32. (Pubitemid 39546403)
2. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409-18.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74. (Pubitemid 32878711)
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502. (Pubitemid 43854964)
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
6. Kim YK, Choi HY, Kim NH, Lee W, Seo DW, Kang DW, et al. Reversine stimulates adipocyte differentiation and downregulates Akt and p70(s6k) signaling pathways in 3T3-L1 cells. Biochem Biophys Res Commun. 2007;358:553-8. (Pubitemid 46755739)
7. Anastasia L, Sampaolesi M, Papini N, Oleari D, Lamorte G, Tringali C, et al. Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle. Cell Death Differ. 2006;13:2042-51. (Pubitemid 44742687)
8. Saraiya M, Nasser R, Zeng Y, Addya S, Ponnappan RK, Fortina P, et al. Reversine enhances generation of progenitor-like cells by dedifferentiation of annulus fibrosus cells. Tissue Eng Part A. 2010;16:1443-55.
9. Jung DW, Williams DR. Novel chemically defined approach to produce multipotent cells from terminally differentiated tissue syncytia. ACS Chem Biol. 2011;6:553-62.
10. Anastasia L, Pelissero G, Venerando B, Tettamanti G. Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. Cell Death Differ. 2010;17:1230-7.
11. D'Alise AM, Amabile G, Iovino M, Di Giorgio FP, Bartiromo M, Sessa F, et al. Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Mol Cancer Ther. 2008;7:1140-9.
12. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010;16:483-9.
13. Lee YR, Wu WC, Ji WT, Chen JY, Cheng YP, Chiang MK, et al. Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J Biomed Sci. 2012;19:9.
14. Hua SC, Chang TC, Chen HR, Lu CH, Liu YW, Chen SH, et al. Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells. Pharm Res. 2012;29:1990-2005.
15. Hsieh TC, Traganos F, Darzynkiewicz Z, Wu JM. The 2,6- disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells. Int J Oncol. 2007;31:1293-300.
16. Perreira M, Jiang JK, Klutz AM, Gao ZG, Shainberg A, Lu C, et al. "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005;48:4910-8. (Pubitemid 41033133)
17. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2:21-32. (Pubitemid 33676958)
18. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17:3052-65. (Pubitemid 28254378)
19. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst. 2002;94:1320-9.
20. Zhu J, Abbruzzese JL, Izzo J, Hittelman WN, Li D. AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet. 2005;159:10-7. (Pubitemid 40614717)
21. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, et al. Activation and overexpression of centrosome kinase BTAK/ Aurora-A in human ovarian cancer. Clin Cancer Res. 2003;9:1420-6. (Pubitemid 36418396)
22. Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 2001;61:2212-9. (Pubitemid 32692050)
23. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 2004;10:2065-71.
24. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998; 20:189-93. (Pubitemid 28455454)
25. Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res. 1998;58:4811-6. (Pubitemid 28503674)
26. Chieffi P, Cozzolino L, Kisslinger A, Libertini S, Staibano S, Mansueto G, et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate. 2006;66:326-33. (Pubitemid 43191232)
27. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab. 2005;90:928-35. (Pubitemid 40279218)
28. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther. 2006;5:2905-13. (Pubitemid 44849018)
29. Zeng WF, Navaratne K, Prayson RA, Weil RJ. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol. 2007;60:218-21.
30. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009;8:1808-17.
31. Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther. 2010;9:883-94.
32. Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, et al. The role of Aurora-A inhibitors in cancer therapy. Ann Oncol. 2007; 18 Suppl 6:vi47-52.
33. Acosta JJ, Munoz RM, Gonzalez L, Subtil-Rodriguez A, Dominguez-Caceres MA, Garcia-Martinez JM, et al. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol. 2003;17:2268-82. (Pubitemid 37352537)
34. Furth PA, Nakles RE, Millman S, Diaz-Cruz ES, Cabrera MC. Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res. 2011;13:220.
35. Bjorge JD, Pang AS, Funnell M, Chen KY, Diaz R, Magliocco AM, et al. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS ONE. 2011;6:e19309.
36. Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011;17:6905-13.
37. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121:2723-35.
38. Gupta N, Grebhardt S, Mayer D. Janus kinase 2 - a novel negative regulator of estrogen receptor alpha function. Cell Signal. 2012;24:151-61.
39. Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, Wappenschmidt B, Meindl A, et al. Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer. 2007;14:267-77. (Pubitemid 47242628)
40. Lin KL, Su JC, Chien CM, Tseng CH, Chen YL, Chang LS, et al. Naphtho[1,2-b]furan-4,5-dione disrupts Janus kinase-2 and induces apoptosis in breast cancer MDA-MB-231 cells. Toxicol In Vitro. 2010;24:1158-67.